Oregon House honors Dr. Brian Druker for cancer research leadership

The Oregon State Legislature convened on May 7, 2025, to honor Dr. Brian Druker, a pivotal figure in cancer research, through House Concurrent Resolution 3 (HCR 3). This resolution recognizes Dr. Druker's extraordinary contributions to cancer treatment, particularly his development of the groundbreaking drug Gleevec, which has transformed the lives of countless patients, including those in Oregon.

During the session, Representative Pham shared a deeply personal account of his battle with chronic myeloid leukemia, highlighting how Dr. Druker's innovative work provided him with life-saving treatment. Pham's story underscored the profound impact of Dr. Druker's research, illustrating not only the scientific advancements but also the human stories behind them. He expressed gratitude for the care he received, which allowed him to thrive and serve others in his community.

Other legislators echoed Pham's sentiments, praising Dr. Druker's dedication and perseverance in the face of challenges throughout his career. They emphasized the importance of his work, which has not only advanced cancer treatment but also inspired hope among patients and families affected by the disease.

The resolution passed with unanimous support, reflecting a collective appreciation for Dr. Druker's legacy and ongoing contributions to the fight against cancer. As the session concluded, the legislators took a moment to acknowledge the significance of Dr. Druker's work, which continues to resonate within the community and beyond.

This recognition serves as a reminder of the vital role that dedicated individuals play in advancing public health and the importance of supporting ongoing research and innovation in the medical field. The legislature's tribute to Dr. Druker not only honors his past achievements but also reinforces the commitment to improving cancer care for future generations.